Violation Tracker Parent Company Summary
|Top 5 Offense Groups (Groups Defined)||Penalty Total||Number of Records|
|Top 5 Primary Offense Types||Penalty Total||Number of Records|
|off-label or unapproved promotion of medical products||$3,019,361,860||5|
|drug or medical equipment safety violation||$880,750,000||4|
|False Claims Act and related||$383,656,216||12|
|kickbacks and bribery||$125,000,000||2|
Parent-subsidiary linkages are based on relationships current as of the latest revision listed in the Update Log, which may vary from what was the case when a violation occurred. The penalty totals are adjusted to account for the fact that the individual entries below may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. The totals are also adjusted to reflect cases in which federal and state or local agencies cooperated and issued separate announcements of the outcome. Duplicate or overlapping penalty amounts are marked with an asterisk in the list below.
For an overview of this company's accountability track record, read its Corporate Rap Sheet here.
For more details on misconduct by this company, see its entry in the Project On Government Oversight's Federal Contractor Misconduct Database.
Subsidy Tracker data on financial assistance to this company by federal, state and local government agencies can be found here.
For an overview of assistance this company is receiving under the CARES Act, see its Covid Stimulus Watch summary page here.
Individual Penalty Records:Click on the company or penalty amount for more information on each case.
|Company||Primary Offense Type||Year||Agency||Penalty Amount|
|Block Drug Company Incorporated||wage and hour violation||2011||WHD||$352,773|
|GlaxoSmithKline Holdings (Americas)||tax violations||2006||IRS||$3,400,000,000|
|GlaxoSmithKline||price-fixing or anti-competitive practices||2006||MULTI-AG||$14,000,000|
|GlaxoSmithKline||price-fixing or anti-competitive practices||2006||MULTI-AG||$3,500,000|
|SmithKline Beecham Corp.||price-fixing or anti-competitive practices||2005||MULTI-AG||$10,000,000|
|GlaxoSmithKline LLC||off-label or unapproved promotion of medical products||2012||FDA||$3,000,000,000|
|GlaxoSmithKline||off-label or unapproved promotion of medical products||2012||MULTI-AG||(*) $477,792,391|
|GlaxoSmithKline||off-label or unapproved promotion of medical products||2010||KY-AG||$3,700,000|
|GlaxoSmithKline||off-label or unapproved promotion of medical products||2009||KY-AG||$661,860|
|GlaxoSmithKline, LLC||off-label or unapproved promotion of medical products||2013||MD-AG||$15,000,000|
|GlaxoSmithKline plc||kickbacks and bribery||2016||SEC||$20,000,000|
|GlaxoSmithKline, LLC||kickbacks and bribery||2014||MULTI-AG||$105,000,000|
|GlaxoSmithKline||False Claims Act and related||2005||DOJ_CIVIL||$150,000,000|
|SmithKline Beecham||False Claims Act and related||2003||DOJ_CIVIL||$47,000,000|
|GlaxoSmithKline||False Claims Act and related||2003||MULTI-AG||$40,000,000|
|GlaxoSmithKline||False Claims Act and related||2005||MULTI-AG||(*) $10,000,000|
|GlaxoSmithKline||False Claims Act and related||2006||GA-AG||$418,952|
|GlaxoSmithKline||False Claims Act and related||2012||ID-AG||$2,600,000|
|GlaxoSmithKline||False Claims Act and related||2011||KS-AG||$4,250,000|
|GlaxoSmithKline||False Claims Act and related||2012||LA-AG||$10,000,000|
|GlaxoSmithKline LLC||False Claims Act and related||2010||HI-AG||$3,333,333|
|GlaxoSmithKline||False Claims Act and related||2006||MULTI-AG||$70,000,000|
|SmithKline Beecham Corp.||False Claims Act and related||2007||TX-AG||$1,400,000|
|GlaxoSmithKline LLC||False Claims Act and related||2019||IL-AG||$54,653,931|
|GlaxoSmithKline Vaccines||environmental violation||2014||EPA||$172,900|
|GlaxoSmithKline LLC||environmental violation||2014||EPA||$317,550|
|GLAXOSMITHKLINE LLC||environmental violation||2016||PA-ENV||$5,259|
|GlaxoSmithKline LLC||environmental violation||2015||NY-ENV||$24,200|
|GLAXOSMITHKLINE, LLC||environmental violation||2014||EPA||(*) $317,550|
|GLAXOSMITHKLINE VACCINES||environmental violation||2014||EPA||(*) $172,900|
|SB Pharmco Puerto Rico Inc.||drug or medical equipment safety violation||2010||FDA||$750,000,000|
|GlaxoSmithKline LLC||drug or medical equipment safety violation||2012||MULTI-AG||$90,000,000|
|GlaxoSmithKline, LLC||drug or medical equipment safety violation||2011||MULTI-AG||$40,750,000|
|SB Pharmco Puerto Rico Inc.||drug or medical equipment safety violation||2010||MULTI-AG||(*) $163,560,000|
|GLAXO SMITH KLINE||aviation safety violation||2014||FAA||$59,500|